Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Grande Portage Resources (V.GPG) Initiates Sensor-Based Ore Sorting Testwork (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Hansa Biopharma Ord Shs HNSBF

Healthcare Biotechnology
Hansa Biopharma AB, formerly Hansa Medical AB, is a Sweden-based biopharmaceutical company with focus on immunomodulatory enzymes for treatment and prevention of rare and severe autoimmune conditions and transplant rejection. The Company’s operations consist of research and development for drug discovery. The Company conducts several projects, among which primary are IdeS (Immunoglobulin G... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (GREY:HNSBF)

Hansa Biopharma to attend 2025 J.P. Morgan Healthcare Conference

PR Newswire 1 day ago

Hansa Biopharma to present data at 2024 American Transplant Congress annual meeting

PR Newswire May 21, 2024

Imlifidase met primary endpoint in 16-HMedIdes-12 phase 2 trial in patients with AMR following kidney transplantation

PR Newswire December 14, 2023

Hansa Biopharma interim report January-March 2023

PR Newswire April 20, 2023

The Scottish Medicines Consortium (SMC) recommends use of Hansa Biopharma's Idefirix[®] (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients

PR Newswire September 12, 2022

Hansa Biopharma announces $70 million non-dilutive product finance transaction with NovaQuest to support continued development of the company's antibody-cleaving enzyme technology platform

PR Newswire July 18, 2022

The Nomination Committee in Hansa Biopharma proposes Peter Nicklin as new chair of the Board of Directors at the Annual General Meeting 2022

PR Newswire May 30, 2022

Hansa Biopharma announces positive early access decision by French Haute Autorité de Santé to use Idefirix® (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients

PR Newswire February 26, 2022

Hansa Biopharma provides business update including certain key financials

PR Newswire January 9, 2022
View More News ››

Opinion & Analysis (GREY:HNSBF)

No current opinion is available.
View More Opinion ››

Bullboard Posts (GREY:HNSBF)

Be the first to post on this bullboard.

Centurion Minerals Ltd

Centurion Minerals Ltd

Centurion Minerals Ltd. is a Canadian-based company with a focus on mineral asset exploration and development in the Americas ...
View More »